SOURCE: BIOLASE Technology, Inc.

BIOLASE Technology, Inc.

May 24, 2010 06:00 ET

BIOLASE Signs Agreement With Procter & Gamble for Light-Based Oral Care Devices

IRVINE, CA--(Marketwire - May 24, 2010) -  BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that it has signed a license agreement with The Procter & Gamble Company (P&G) to enable BIOLASE to launch light-based oral care devices to dental professionals. Negotiations concluded late last week with the signing of the agreement at P&G headquarters in Cincinnati. BIOLASE currently plans to market the new products to professionals through its primary distribution partner Henry Schein (NASDAQ: HSIC) and its other distribution partners around the world.

"This agreement on implementing a product launch is an important milestone in our partnership with Procter & Gamble, a proven, global leader in the development, sales and marketing of professional and consumer products," said BIOLASE Chief Executive Officer David M. Mulder. "We believe this product will further extend our brand nationally and globally and will bring us closer to consumers through the professional market. We have a long-term strategy of making the benefits of all our products, particularly the Waterlase®, well known to consumers."

Further details of the agreement and the products will be released in the coming months and will be included in a corresponding filing by BIOLASE with the Securities and Exchange Commission.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (, the world's leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology, pain management and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti (investors)
    Len Hall (media)
    Allen & Caron